Opioid Publications

2025

• Yakovenko I, Mukaneza Y, Germé K, Belliveau J, Fraleigh R, Bach P, Poulin G, Selby P, Goyer MÈ, Brothers TD, Rehm J, Hodgins DC, Stewart SH, Wood E, Bruneau J; au nom de l’équipe chargée de l’élaboration des lignes directrices de l’Initiative canadienne de recherche sur les impacts des substances psychoactives. (2025). Prise en charge du trouble lié à l’usage d’opioïdes : mise à jour 2024 du guide de pratique clinique nationale. CMAJ. 197(4):E99-E111. French.
• Mathias H, Auger S, Schulz P, Hyshka E. (2025). Including Families in a Response to the Unregulated Toxic Drug Crisis: A Call to Action. Subst Use Misuse. 60(3):452-456.
• Zolopa C, Brothers TD, Leclerc P, Mary JF, Morissette C, Bruneau J, Martin NK, Hyshka E, Larney S. (2025). Characteristics of supervised injection site clients and factors associated with requiring overdose intervention, Montreal, Canada, 2018-2022. Int J Drug Policy. 137:104711.
• Navarrete J, Hughes C, Kung JY, Salokangas E, Taylor M, Hyshka E. (2025). Implementation of harm reduction services for people who use drugs provided by pharmacy staff: a scoping review protocol. BMJ Open. 15(3):e093272.
• Gadimova, F; Jackson, J. (2025). Experiences of Healthcare Professionals Working in Injectable Opioid Agonist Treatment Programs: A Qualitative Thematic Analysis. Journal of Addictions Nursing. 36(1):p 46-52.
• Jackson, J; Ainsley, E; Perry, S; Gadimova, F; Ens, T; Cameron, T; Francisco, R; Hon, A; Kim, Y; McGill, E; Patel, T; Sodhi, S; Yu, J; Ginn, C. (2025). How Do We Move the Needle on Needle Debris? A Qualitative Interview Study With Reflexive Thematic Analysis, From SANDS (Strategies for Addressing Needle Debris Study). The Canadian Journal of Addiction. 16(1):p 24-34.

2024

• Chan RRD, Yakiwchuk EM, Halpape K. (2024). Take-Home Naloxone Access and Use among Older Adults Living with Pain: A Scoping Review. Can J Hosp Pharm. 13;77(1):e3506.
• Rattanavong M, Kwan D, Jorgenson D, Landry E, Marwah R, Halpape K. (2024). Low-dose Initiation of Buprenorphine/naloxone for the Management of Chronic Non-cancer Pain in Patients on Long-term Opioid Therapy: A Case Series. Can J Pain. 8(1):2310811.
• Nguyen T, Bareham J, Halpape K. (2024). Barriers and facilitators for family physicians prescribing opioid agonist therapy in Saskatchewan. Can Fam Physician. 70(4):e52-e60.
• Yakovenko I, Mukaneza Y, Germé K, Belliveau J, Fraleigh R, Bach P, Poulin G, Selby P, Goyer MÈ, Brothers TD, Rehm J, Hodgins DC, Stewart SH, Wood E, Bruneau J; Canadian Research Initiative in Substance Matters guideline development team. (2024). Management of opioid use disorder: 2024 update to the national clinical practice guideline. CMAJ. 196(38):E1280-E1290.
• Cattell C, Hyshka E, Leier B, Mack C. (2024). Capacity, Rationality, and the Promotion of Autonomy: A Trauma-Informed Approach to Refusals of Care After Opioid Poisoning. Am J Bioeth. 24(5):48-51.
• Englander H, Thakrar AP, Bagley SM, Rolley T, Dong K, Hyshka E. (2024). Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review. JAMA Intern Med. 184(6):691-701.
• Hyshka, E., Moore, D.M., Knight, R. et al. (2024). The need for an expanded, evidence-based public health response to the overdose crisis and the toxic drug supply in Canada. Can J Public Health 115;181–185.
• MacKinnon N, Lane D, Scheuermeyer F, Kaczorowski J, Dong K, Orkin AM, Daoust R, Moe J, Andolfatto G, Klaiman M, Yan J, Koh JJ, Crowder K, Atkinson P, Savage D, Stempien J, Besserer F, Wale J, Kestler A. (2024). Factors associated with frequent buprenorphine / naloxone initiation in a national survey of Canadian emergency physicians. PLoS One. 19(2):e0297084.
• Lakkadghatwala R, Lane D, Scheuermeyer F, Hilburt J, Buxton J, Johnson C, Nolan S, Sutherland C, Moe J, Daoust R, Dong K, Christenson J, Miles I, Orkin A, Whyte M, Kestler A. (2024). An emergency-department-initiated outreach program for patients with opioid use disorder is associated with an increase in agonist therapy and engagement in addictions care: a one-year cohort study. Subst Abuse Treat Prev Policy. 19(1):14.

2023

• Stone KD, Scott K, Holroyd BR, Lang E, Yee K, Taghizadeh N, Deol J, Dong K, Fanaeian J, Ghosh M, Low K, Ross M, Tanguay R, Faris P, Day N, McLane P. (2023). Buprenorphine/naloxone initiation and referral as a quality improvement intervention for patients who live with opioid use disorder: quantitative evaluation of provincial spread to 107 rural and urban Alberta emergency departments. CJEM. 25(7):598-607.
• Duncan K, Scheuermeyer F, Lane D, Ahamad K, Moe J, Dong K, Nolan S, Buxton J, Miles I, Johnson C, Christenson J, Whyte M, Daoust R, Garrod E, Badke K, Kestler A. (2023). Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs. CJEM. 25(10):802-807.
• Hassan AN, Bozinoff N, Jutras-Aswad D, Socias ME, Stewart SH, Lim R, Le Foll B; OPTIMA Research Group. (2023). Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial. J Addict Med. 1;17(1):e49-e56.
• Bastien G, McAnulty C, Ledjiar O, Socias ME, Le Foll B, Lim R, Hassan AN, Brissette S, Marsan S, Talbot A, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. (2023). Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial. Can J Psychiatry. 68(8):572-585.
• Elkrief L, Bastien G, McAnulty C, Bakouni H, Hébert FO, Socias ME, Le Foll B, Lim R, Ledjiar O, Marsan S, Brissette S, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. (2023). Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study. J Subst Use Addict Treat. 149:209031.
• Whitehurst DGT, Mah C, Krebs E, Enns B, Socias ME, Jutras-Aswad D, Le Foll B, Nosyk B; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. (2023). Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada. Qual Life Res. 32(8):2209-2221.
• Enns B, Krebs E, Whitehurst DGT, Jutras-Aswad D, Le Foll B, Socias ME, Nosyk B; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. (2023). Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder. Drug Alcohol Depend. 1;247:109893.
• Mocanu V, Bozinoff N, Wood E, Jutras-Aswad D, Le Foll B, Lim R, Cheol Choi J, Yin Mok W, Eugenia Socias M; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. (2023). Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial. Drug Alcohol Depend. 1;248:109932.
• Bakouni H, McAnulty C, Tatar O, Socias ME, Foll BL, Lim R, Ahamad K, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. (2023). Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study. Am J Addict. 32(5):469-478.
• Crepeault H, Ti L, Jutras-Aswad D, Wood E, Le Foll B, Lim R, Bach P, Brar R, Socias ME. (2023). Correlates of nonfatal overdose among treatment-seeking individuals with non-heroin opioid use disorder: Findings from a pragmatic, pan-Canadian, randomized control trial. J Subst Use Addict Treat. Sep 6:209158.

2022

• Marshall K, Maina G, Sherstobitoff J. (2021). Plausibility of patient-centred care in high-intensity methadone treatment: reflections of providers and patients. Addict Sci Clin Pract. 16(1):42.
• Maina G, Marshall K, Sherstobitof J. (2021). Untangling the Complexities of Substance Use Initiation and Recovery: Client Reflections on Opioid Use Prevention and Recovery From a Social-Ecological Perspective. Subst Abuse. 13;15:11782218211050372.
• Marshall T, Hancock M, Kinnard EN, Olson K, Abba-Aji A, Rittenbach K, Stea JN, Tanguay R, Vohra S. (2021). Treatment options and shared decision-making in the treatment of opioid use disorder: A scoping review. J Subst Abuse Treat. 135:108646. doi: 10.1016/j.jsat.2021.108646.
• Deschamps J, Gilbertson J, Straube S, Dong K, MacMaster FP, Korownyk C, Montgomery L, Mahaffey R, Downar J, Clarke H, Muscedere J, Rittenbach K, Featherstone R, Sebastianski M, Vandermeer B, Lynam D, Magnussen R, Bagshaw SM, Rewa OG. (2021).  Association between supportive interventions and healthcare utilization and outcomes in patients on long-term prescribed opioid therapy presenting to acute healthcare settings: a systematic review and meta-analysis. BMC Emerg Med. 21(1):17. doi: 10.1186/s12873-020-00398-9.
• Lee C, Lin M, Martins KJB, Dyck JRB, Klarenbach S, Richer L, Jess E, Hanlon JG, Hyshka E, Eurich DT. (2021). Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada. BMC Public Health. 21(1):843. doi: 10.1186/s12889-021-10867-w. 
• Kestler, A., Kaczorowski, J., Dong, K., Orkin, A., Daoust, R., Moe, J., et.al. (2021). A cross-sectional survey on buprenorphine-naloxone practice and attitudes in 22 Canadian emergency physician groups: a cross-sectional study. CMAJ Open. 9(3):E864-E873.
• Bristowe, S., Ghosh, S., Trew, M., CMHA., Rittenbach, K. (2021). Virtual Overdose Response for People Who Use Opioids Alone: Protocol for a Feasibility and Clinical Trial Study.
  JMIR Res Protoc. 12;10(5):e20183.
• Moustaqim-Barrette, A., Dhillon, D., Ng J., Sundvick, K., Ali, F., Elton-Marshall, T., Leece, P., Rittenbach, K., Ferguson, M., Buxton, J.A. (2021). Take-home naloxone programs for
  suspected opioid overdose in community settings: a scoping umbrella review. BMC Public Health. 21:597.
• Wild, T.C., Hammal, F., Hancock, M., Bartlett, N.B., Kaiser Gladwin, K., Adams, D., Loverock, A., H0dgins, D.C. (2021). Forty-eight years of research on psychosocial interventions in the treatment of opioid use disorder: A scoping review. Drug and Alcohol Dependence. 218.

2020

• Bahji A, Danilewitz M, Crockford D. (2020). Response to Canadian Psychiatric Association. Opioid Use Disorder Position Statement: More than Just Collaborators in Care. Canadian Journal of Psychiatry. 59:37-50.
• Bahji A, Cheng B, Gray S, Stuart H. (2020). Mortality among people with opioid use disorder: a systematic review and meta-analysis. American Journal of Addiction Medicine. 14(4):e118-e132.
• Bahji A. (2020). Incidence and correlates of opioid-related psychiatric emergency care: a retrospective, multi-year cohort study. Journal of Opioid Management. 16(3): 223-226.
• Bahji A. (2020). Commentary on Hayes et al. (2019): The harms of opioid dose escalation in the management of chronic non-cancer pain. Addiction. 115(6): 1113-1114.
• Bahji A, Carlone D, Altomare J. (2020). Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis. Addiction. 115(8): 1413-1425.
• Kaczorowski, J., Bilodeau, J., Orkin, A.M., Dong, K., Daoust, R., & Kestler, A. (2020). Emergency Department-initiated Interventions for Patients with Opioid Use Disorder: A Systematic Review. Academic Emergency Medicine.
• Kosteniuk, B. and Dell, C. (2020). How companion animals support recovery from opioid addiction: An exploratory study of patients in a methadone maintenance treatment program. APORIA Journal. 12(1).

2019

• Bahji A, Cheng B, Gray S, Stuart H. (2019). Reduction in mortality risk with opioid agonist therapy: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica. 140(4): 313-339.
• Bahji A, Camire D. (2019). The Local Response to the Canadian Opioid Epidemic in the Kingston, Frontenac, and Lennox & Addington communities. Health Promotion and Chronic Disease Prevention in Canada. 39(12): 333-336.
• Bahji A. (2019). Effectiveness of Naltrexone for Opioid Use Disorder among Inmates: A Systematic Review and Meta-Analysis. Journal of Advancement in Criminal Justice. 2:73-92.
• Bahji A, Bajaj N. (2019). The value of hospitalization in the opioid epidemic: a scoping review. Canadian Journal of Addiction. 10(2): 6-17.
• Bucerius, Sandra, Kevin D. Haggerty. (2019) Fentanyl Behind Bars: The Implications of Synthetic Opiates on Prisoners and Correctional Officers. International Journal of Drug Policy. 71, 133-138.
• Jun E, Ali S, Yaskina M, Dong K, Rajagopal M, Drendel AL, Fowler M, Poonai N. (2019). A two-centre survey of caregiver perspectives on opioid use for children’s acute pain. Paediatrics & Child Health. pxz162.
• Koh J, Paterson QS, Ong M, Martin LJ, Woods RA, Dong K. (2019). Addressing the opioid crisis in the era of competency-based medical education: recommendations for emergency department interventions. Canadian Journal of Emergency Medicine. 21(4): 452-454.
• Maina G, Tahir H, Docabo A, Kahia N, Brunelle C. (2019). Exploring health-care providers’ experiences in the care of clients on opioid agonist treatment in two western Canadian clinics. Can J Nurs Res. 844562119842751.
• Maina G, Crizzle A, Maposa S, Fournier B. (2019). Sociodemographic Profiles and Clinical Outcomes for Clients on Methadone Maintenance Treatment in a Western Canadian Clinic: Implications for Practice. J Forensic Nurs.
• Nixon LL, Marlinga JC, Hayden KA, Mrklas KJ. (2019). Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review. Syst Rev. 8(1):186
• Peckham AM, Fairman KA, Awanis G, Early NK. (2019). High-risk opioid prescribing trends in the outpatient setting prior to issuance of federal guidance. Prev Med Rep. 15:100892.

2018

• Bahji A, Bajaj N. (2018). Opioids on trial: A systematic review of interventions for the treatment and prevention of opioid overdose. Canadian Journal of Addiction. 9(1): 26-33.
• Bahji A, Camire D. (2018). Letter to the Editor: A Case for Opioid Education and Training for Medical Students, Residents, and Allied Health Staff: Response To “Educational Intervention for Physicians to Address the Risk of Opioid Abuse.” Journal of Opioid Management. 14(3): 157.
• Bruneau, J., Ahamad, K., Goyer, M., Poulin, G., Selby, P., Fischer, B., Wild, T.C., & Wood, E. (2018).  Management of opioid use disorders: Clinical practice guideline synopsis.  Canadian Medical Association Journal. 190(9), E247-E257.
• Marshall, T., Kinnard, E.N., Hancock, M., Jones, S.K., Olson, K., Abba-Aji, A., Rittenbach, K., Vohra, S. (2018). Patient Engagement, Treatment Preferences and Shared Decision-Making (SDM) in the Treatment of Opioid Use Disorder (OUD) in Adults: A Scoping Review Protocol. British Medical Journal Open 8(10), e022267.

2017

• Freeman, L.K., Bourque, S., Etches, N., Goodison, K., O’Gorman, C., Rittenbach, K., Sikora, C.A., Yarema, M. (2017). Alberta’s provincial take-home naloxone program: A multi-sectoral and multi-jurisdictional response to overdose. Canadian Journal of Public Health. 108(4):e398-e402.

2014

• Christensen DR, Landes RD, Jackson L, Marsch LA, Mancino MJ, Chopra MP, Bickel WK. (2014). Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 82(6):964-72.

2013

• Kerr T, Small W, Hyshka E, Maher L, Shannon K. (2013). ‘It’s more about the heroin’: injection drug users’ response to an overdose warning campaign in a Canadian setting. Addiction. 108(7), 1270-6.

2012

• Landes RD, Christensen DR, Bickel WK. (2012). Delay discounting decreases in those completing treatment for opioid dependence. Exp Clin Psychopharmacol. 20(4):302-9.

2005 

• Leri F, Stewart J, Fischer B, Jürgen R, Marsh DC, Brissette S, Bruneau J, El-Guebaly N, Noël L, Tyndall MW, Wild TC. (2005). Patterns of opioid and cocaine co-use: a descriptive study in a Canadian sample of untreated opioid-dependent individuals. Exp Clin Psychopharmacol. 13(4), 303-10.
• Wild TC, el-Guebaly N, Fischer B, Brissette S, Brochu S, Bruneau J, Noël L, Rehm J, Tyndall M, Mun P. (2005). Comorbid depression among untreated illicit opiate users: results from a multisite Canadian study. Can J Psychiatry. 50(9), 512-8.